Table 1.
DRUG | INDICATION | PHASE | TREATMENT | TRIAL | STATUS |
---|---|---|---|---|---|
TH-302 | Pancreatic Ca | I–III | TH-302 +/− Gemcitabine | NCT01746979, NCT01144455, NCT01833546 | completed |
| |||||
Soft Tissue Sarcoma | I/II–III | TH-302 +/− Doxorubicin | NCT01440088, NCT00742963 | completed | |
| |||||
Biliary Tract Ca | II | TH-302 Monotherapy | NCT02433639 | recruiting | |
| |||||
Glioblastoma | II | TH-302 + Bevacizumab | NCT02342379 | recruiting | |
| |||||
High Grade Glioma | II | TH-302 MonotherapyàBevacizumab | NCT01403610 | completed | |
| |||||
MM | II | TH-302 +/− Dexamethasone +/− Bortezomib/Pomalidomide | NCT01522872 | active, NR | |
| |||||
Melanoma | II* | TH-302 Monotherapy | NCT01864538* | active, NR | |
| |||||
Solid Tumors | I–I/II | TH-302 + Gemcitabine/Docetaxel/Pemetrexed TH-302 + Pazopanib TH-302 Monotherapy |
NCT00743379, NCT00495144, NCT02020226, NCT01485042, NCT01833546, NCT02076230* |
completed active, NR |
|
| |||||
RCC, GIST, pNET | I I* II |
TH-302 + Sunitinib TH-302 [14C] TH-302 + Sunitinib |
NCT01381822 NCT02076230 NCT02402062 |
active completed active, NR |
|
| |||||
HCC | I | TH-302 + Doxorubicin (TACE) | NCT01721941 | NYR | |
| |||||
AML, ALL, CML, MDS | I | TH-302 Monotherapy | NCT01149915 | completed | |
| |||||
TIRAPAZAMINE | SCLC | II* I |
Tirapazamine + Cisplatin, Etoposide, RT Tirapazamine +/− Cisplatin+ Etoposide+ RT |
NCT00066742 NCT00006487 |
completed |
| |||||
NSCLC | III I |
Tirapazamine +/− Carboplatin+Paclitaxel Tirapazamine + Carboplatin, Paclitaxel, RT |
NCT00006484 NCT00033410 |
completed | |
| |||||
Cervical Ca Ovarian Ca Peritoneal Cavity Ca |
III II I |
Tirapazamine +/− Cisplatin, RT Tirapazamine + Cisplatin Tirapazamine + Cisplatin, RT |
NCT00262821 NCT00003369 NCT00098995 NCT00020696 |
completed | |
| |||||
HCC | I | Tirapazamine (TAE) | NCT02174549 | recruiting | |
| |||||
SCCHN | II, III | Tirapazamine +/− Cisplatin, 5-FU, RT | NCT00002774, NCT00174837 | completed | |
| |||||
Childhood Solid Tumor | I | Tirapazamine + Cyclophosphamide+ GCSF | NCT00003288 | completed | |
| |||||
Head and Neck Tumor | III | Tirapazamine +/− Cisplatin, RT | NCT00094081 | completed | |
| |||||
Childhood Rhabdomyosarcoma | II* | Tirapazamine + Polychemotherapy *** | NCT00025363 | completed | |
| |||||
TH-4000 | NSCLC Recurrent/Metastatic SCCHN |
II | TH-4000 Monotherapy | NCT02454842 NCT02449681 |
active, active, NR |
| |||||
EO9 | Bladder Cancer | I–III | EO9 Monotherapy | NCT01373398, NCT00598806, NCT00141531 NCT01469221 |
completed active, NR |
III | EO9 Monotherapy pre TURB | NCT00461591 NCT02563561 |
completed active, NR |